San Diego-based Zogenix, a developer of needle-free, delivery systems for the treatment of acute migraines and cluster headaches, has filed for a $90M IPO. The IPO is being underwritten by Wells Fargo Securities, Leerink Swann, Oppenheimer & Co., and Stifel Nicolaus Weisel. The firm is venture backed by Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Chicago Growth Partners, Abingworth Bioventures, and others. Zogenix said it is looking to list on the NASDAQ Global Market as ZGNX. The company reported $7.5M in revenues for the six months ended June 30, 2010, with a net loss of $49.3M.